Method for producing fibrin sheet

By adding fibrinogen solution and thrombin to a gelatin hydrogel substrate and combining it with support membrane technology, the concentration and shape problems in fibrin sheet manufacturing were solved, enabling the manufacture of uniform sheets with cell safety at low concentrations, which is suitable for 3D tissue construction and cell therapy.

CN114466922BInactive Publication Date: 2024-11-08OSAKA UNIVERSITY
View PDF 17 Cites 0 Cited by

Patent Information

Application Number
CN202080069256.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-10-01
Filing Date
2020-09-09
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In existing technologies, when manufacturing fibrin sheets, excessively high fibrin concentrations can damage cells, while excessively low concentrations make it difficult to maintain the shape. Furthermore, the process is complex and it is difficult to achieve uniform and arbitrary shapes.

Method used

By adding fibrinogen solution and thrombin to a gelatin hydrogel substrate, fibrin sheets are formed using a supporting membrane, and the substrate is separated at the gelatin melting temperature, thus achieving uniform formation and separation of fibrin sheets.

Benefits of technology

It enables the easy manufacture of uniform, arbitrary-shaped fibrin sheets while inhibiting cell damage at low concentrations, making it suitable for 3D tissue construction and cell replenishment therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003575054450000011
    Figure HDA0003575054450000011
  • Figure HDA0003575054450000012
    Figure HDA0003575054450000012
  • Figure HDA0003575054450000013
    Figure HDA0003575054450000013
Patent Text Reader

Abstract

A method for producing a fibrin sheet is a method for producing a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel, comprising: step 1, dripping a fibrinogen solution containing at least one selected from cells and drugs and fibrinogen onto the surface of a substrate formed by a gelatin hydrogel; step 2, adding thrombin to the fibrinogen solution on the surface of the substrate; step 3, placing a support membrane in contact with the upper surface of the fibrinogen solution to which the thrombin is added; step 4, forming a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel between the substrate and the support membrane through the reaction of fibrinogen and thrombin; and step 5, melting the substrate at a temperature above the melting temperature of the gelatin hydrogel to separate the fibrin sheet supported by the support membrane from the substrate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a fibrin sheet, and more particularly, to a method for producing a fibrin sheet comprising a fibrin gel containing at least one selected from cells and a drug. Background Art

[0002] In the field of regenerative medicine, from the perspective of supplementing lost organ functions, expectations for treatment methods that construct cells into three-dimensional tissues and organs for transplantation have increased (e.g., Kawamura M. et al., Circulation, 2012; 126: S29-37 (non-patent document 1), Miyagawa S. et al., Current Gene Therapy, 2016, Vol. 16, No. 1, p. 5-13 (non-patent document 2)). In the construction of three-dimensional tissues and organs, in order to obtain better therapeutic effects, it is also necessary to produce tissues containing a sufficient number of cells up to several layers. Therefore, in recent years, the Layer by Layer method (LbL method) of stacking cells using a 3D printer has been studied (for example, Takagi D. et al., Ricoh Technical Report, 2016, No. 41, p. 118-127 (non-patent document 3)), the method of making nanofibers and seeding cells thereon (for example, Li J. et al., Stem Cell Reports, 2017, Vol. 9, 1-14, p. 1546-1559 (non-patent document 4)), the method of making a special mold and seeding it with the above-mentioned biocompatible materials and cells (Nakane T. et al., Scientific Report, 2017, 7: 45641 (non-patent document 5), Gao L. et al., Circulation, 2018; 137: 1712-1730 (non-patent document 6), Shadrin IY. et al., Nature Communications, 2017;8:1825 (non-patent document 7)) etc.

[0003] However, the LbL method requires a special 3D printer that can inoculate cells, the method using nanofibers requires a device for making the nanofibers and time after inoculation until the cells are fully implanted, and the method using a special mold requires the making of the special mold and time to culture the cells in the mold. These existing methods have the problem of requiring special and expensive devices and time.

[0004] In addition, in the field of regenerative medicine, it is known that in order to regenerate tissue, a cell supplement therapy using a cell sheet containing cells in a lesion or defective part is used. It is also further studied that the cell sheet is three-dimensionally laminated to construct the above-mentioned 3D tissues and organs for transplantation, drug development research, etc. Relatedly, it is known that in surgical operations, a sheet formed by a biocompatible material is used to patch / enhance the tissue defective part after the incision and / or lesion removal, and it is also known that the sheet is further made to contain a medicament for treatment and to make a pharmaceutical sheet. As the base material (scaffold) of these cell sheets and pharmaceutical sheets, the above-mentioned biocompatible materials, fibrin, collagen, and polylactic acid are widely known. Among them, the fibrin gel formed by fibrin has the advantage of also playing a role as a biological adhesive by tissue adhesion, but on the other hand, because it is in a paste state, if the concentration of fibrin is concentrated in order to make the operation easier, it is difficult to make the contained cells survive. On the contrary, if fibrin is diluted until the concentration at which cells can survive, it is not easy to maintain the shape of the gel, so the operation becomes difficult. Furthermore, due to the strong adhesiveness, there are problems such as damage to cells during the recovery of cell sheets, or difficulty in manufacturing / maintaining uniform and arbitrarily shaped cell sheets. In addition, assuming that the automation of the equipment used in the manufacture of cell sheets, drug sheets, etc. will become the mainstream in the future, it is expected that a simpler manufacturing method will be required from the perspective of improving the maintainability and miniaturization of the equipment.

[0005] Prior art literature

[0006] Non-patent literature

[0007] Non-patent literature 1: Kawamura M. et al., Circulation, 2012; 126: S29-37

[0008] Non-patent document 2: Miyagawa S. et al., Current Gene Therapy, 2016, Vol. 16, No. 1, p. 5-13

[0009] Non-patent document 3: Takagi D. et al., Ricoh Technical Report, 2016, No. 41, p. 118-127

[0010] Non-patent document 4: Li J. et al., Stem Cell Reports, 2017, Vol. 9, 1-14, p. 1546-1559

[0011] Non-patent literature 5: Nakane T. et al., Scientific Report, 2017, 7: 45641

[0012] Non-patent literature 6: Gao L. et al., Circulation, 2018; 137: 1712-1730

[0013] Non-patent literature 7: Shadrin IY. et al., Nature Communications, 2017; 8: 1825 Summary of the invention

[0014] Problems to be solved by the invention

[0015] The present invention has been proposed in view of the problems of the above-mentioned prior art, and its purpose is to provide a method for producing a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel, which can suppress damage to cells and drugs even when the fibrin concentration is a low concentration at which cells can survive, and can be easily produced uniformly and in an arbitrary shape.

[0016] Methods for solving problems

[0017] The present inventors have conducted intensive studies on a method for producing a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel in order to achieve the above-mentioned object. As a result, it has been found that, by dripping a fibrinogen solution containing the above-mentioned cells and / or drugs and fibrinogen on the surface of a substrate formed of a gelatin hydrogel, then adding thrombin to the above-mentioned fibrinogen solution on the surface of the above-mentioned substrate to prepare a fibrin precursor solution, and placing the support membrane in contact with the upper surface thereof, the above-mentioned fibrin precursor solution can be spread between the uniform surfaces of the above-mentioned substrate and the above-mentioned support membrane by surface tension, and the above-mentioned fibrinogen and thrombin react to form the above-mentioned fibrin sheet uniformly without using an operation such as spreading that may cause mechanical damage to the cells. It has also been found that, by melting the above-mentioned substrate at a temperature higher than the melting temperature of the above-mentioned gelatin hydrogel after the above-mentioned fibrin sheet is formed, the above-mentioned fibrin sheet can be easily separated from the above-mentioned substrate regardless of the fibrin concentration in the above-mentioned fibrin sheet, even if the concentration is a low concentration at which cells can survive. Furthermore, the inventors have found that a fibrin sheet of any shape can be easily obtained by adjusting the shape of the support membrane, thereby completing the present invention.

[0018] That is, the present invention includes the following aspects. [1]

[0020] A method for producing a fibrin sheet, comprising the steps of:

[0021] Step 1, dropping a fibrinogen solution containing at least one selected from cells and drugs and fibrinogen onto the surface of a substrate formed of gelatin hydrogel;

[0022] Step 2, adding thrombin to the fibrinogen solution on the surface of the substrate;

[0023] Step 3, placing the support membrane in contact with the upper surface of the fibrinogen solution to which the thrombin is added;

[0024] Step 4, forming a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel by reacting fibrinogen with thrombin between the substrate and the support membrane; and

[0025] In step 5, the base material is melted at a temperature not lower than the melting temperature of the gelatin hydrogel, and the fibrin sheet supported by the support membrane is separated from the base material. [2]

[0027] The method for producing a fibrin sheet according to [1], wherein the fibrin sheet is a cell sheet containing at least cells in the fibrin gel, and the substrate is a substrate for cell culture. [3]

[0029] The method for producing a fibrin sheet according to [1] or [2], further comprising, before the step 1, a step of heating an aqueous gelatin solution containing gelatin and water and then cooling it to obtain the gelatin hydrogel. [4]

[0031] The method for producing a fibrin sheet according to any one of [1] to [3], wherein the support film is a polypropylene sheet. [5]

[0033] The method for producing a fibrin sheet according to any one of [1] to [4], wherein in the step 5, the base material is melted at 30 to 40°C.

[0034] Effects of the Invention

[0035] According to the present invention, a method for producing a fibrin sheet can be provided, which can easily produce a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel uniformly and in an arbitrary shape while suppressing damage to cells and drugs even when the fibrin concentration is a low concentration at which cells can survive.

[0036] In addition, by using the fibrin sheet (cell sheet and / or drug sheet) obtained by the present invention and stacking them, it is possible to easily construct three-dimensional tissues, organs and other three-dimensional biological materials in a short time. The fibrin sheet and the three-dimensional biological material can be used for cell supplementation therapy and treatment for chronic diseases and acute diseases, and can also be used for understanding biochemical phenomena and for cell culture that produces useful substances. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 These are photographs showing the morphology of the substrate, the fibrin sheet, and the support membrane in step 4 of Example 1.

[0038] Figure 2 These are photographs showing the morphology of the melted substrate, the fibrin sheet, and the support membrane in step 5 of Example 1.

[0039] Figure 3 This is a photograph showing the morphology of the fibrin sheet obtained in Example 1.

[0040] Figure 4 This is a photograph showing the morphology of a fibrin sheet obtained by enlarging the area.

[0041] Figure 5 This is a graph showing the results of cardiac function evaluation in the evaluation of the fibrin sheet obtained in Example 1.

[0042] Figure 6 This is a graph showing the results of measuring the expression level of the VEGF gene in the evaluation of the fibrin sheet obtained in Example 1. DETAILED DESCRIPTION

[0043] Hereinafter, the present invention will be described in detail according to its preferred embodiments, but the following embodiments are for illustration of the present invention and are not intended to limit the present invention to the following contents. The present invention can be implemented with appropriate modifications within the scope of the gist thereof.

[0044] The method for producing a fibrin sheet of the present invention is characterized in that:

[0045] A method for producing a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel, comprising the following steps:

[0046] Step 1, dropping a fibrinogen solution containing at least one selected from cells and drugs and fibrinogen onto the surface of a substrate formed of gelatin hydrogel;

[0047] Step 2, adding thrombin to the fibrinogen solution on the surface of the substrate;

[0048] Step 3, placing the support membrane in contact with the upper surface of the fibrinogen solution to which the thrombin is added;

[0049] Step 4, forming a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel by reacting fibrinogen with thrombin between the substrate and the support membrane; and

[0050] In step 5, the base material is melted at a temperature not lower than the melting temperature of the gelatin hydrogel, and the fibrin sheet supported by the support membrane is separated from the base material.

[0051] (Fibrin sheet)

[0052] In the present invention, the so-called "fibrin sheet" is a sheet containing a fibrin gel and at least one selected from cells and drugs contained in the fibrin gel. In the present invention, the so-called "fibrin gel" is a polymer formed by the reaction of fibrinogen and thrombin. The fibrin gel mainly has the function of bonding cells to each other.

[0053] The above-mentioned fibrinogen is a protein in the blood, and usually, it can be obtained from the plasma of humans or animals other than humans. From the aspect of biocompatibility, it is desirable to use fibrinogen obtained from human plasma as a raw material when humans are used as the object of the fibrin sheet, and in addition, when animals other than humans are used as the object, fibrinogen obtained from the plasma of the animal is used as a raw material. As such fibrinogen, for example, dry human fibrinogen manufactured in accordance with the biological preparation standard of the Ministry of Health, Labor and Welfare (June 2019), in addition, commercial products can be appropriately used.

[0054] The above-mentioned thrombin is an enzyme that catalyzes the reaction that the above-mentioned fibrinogen becomes fibrin, and usually, it can be obtained from the plasma of humans or animals other than humans. As such thrombin, for example, in Ca 2+ Thrombin prepared by allowing prothrombin purified from human or bovine plasma to act on thromboplastin, snake venom, or the like in the presence of , and commercially available products can be used as appropriate.

[0055] Examples of the fibrin sheets involved in the present invention include cell sheets containing cells in the above-mentioned fibrin gel, drug sheets containing drugs in the above-mentioned fibrin gel, and cell / drug sheets containing cells and drugs in the above-mentioned fibrin gel (in this specification, they are collectively referred to as "cell sheets and / or drug sheets" depending on the circumstances).

[0056] In the present invention, the cells contained in the above-mentioned fibrin gel are not particularly limited as long as they can be transplanted, and can be appropriately selected according to the purpose. They can be any one of omnipotent cells, adult stem cells, precursor cells, and mature cells, and can be only one of them or a combination of two or more.

[0057] As the above-mentioned universal cell, for example, ES cells, GS cells and iPS cells can be enumerated. As the above-mentioned adult stem cells, for example, mesenchymal stem cells (MSC), hematopoietic stem cells, amniotic cells, umbilical cord blood cells, cells derived from bone marrow, myocardial stem cells, stem cells derived from fat and neural stem cells can be enumerated. As precursor cells and mature cells, for example, chondrocytes, cartilage precursor cells, cells derived from synovial membranes, cells derived from fat, myocardial cells, vascular endothelial cells can be enumerated. In addition, cells induced by the above-mentioned universal cells, adult stem cells or precursor cells (for example, cells (myocardial cells, vascular endothelial cells) derived from iPS cells, etc.) can be enumerated. As the source of the above-mentioned cells, mammals (primates such as chimpanzees and monkeys, cattle, pigs, horses, chickens, cats, dogs and other livestock, pets), birds, reptiles, amphibians, fish can be enumerated, and can be autologous cells derived from the object of transplanting fibrin sheets, or can be allogeneic cells derived from the object other than the transplanted object.

[0058] When the fibrin sheet is the cell sheet or the cell / drug sheet, the content of cells contained in the fibrin gel (or the total content of cells when there are two or more types) is preferably 1×10 6 ~1×10 7 In addition, the fibrin gel may contain cells mixed during separation in addition to the above cells (target cells).

[0059] In the present invention, the drugs contained in the fibrin gel include, for example, antitumor agents (alkylating drugs, platinum compounds, antimetabolites, topoisomerase inhibitors, anticancer antibiotics, microtubule-acting anticancer agents, etc.), antibacterial agents (penicillins, cephems, carbapenems, aminoglycosides, quinolones, macrolides, tetracyclines, glycopeptides, etc.), anti-inflammatory agents (steroids, NSAIDs, etc.), antiviral agents, low molecular weight drugs such as hormones; physiologically active peptides such as osteogenic factors and bone growth factors; proteins; glycoproteins; polysaccharides; nucleic acids; nutrients (citric acid, etc.); vitamins; opioids, and may be only one of them or a combination of two or more of them.

[0060] When the fibrin sheet is the drug sheet or the cell / drug sheet, the content of the drug contained in the fibrin gel (or their total content when there are two or more drugs) is appropriately adjusted according to the purpose of use, etc., and therefore cannot be generalized. For example, it is preferably 1 to 40% by mass, more preferably 1 to 30% by mass, and even more preferably 1 to 20% by mass relative to the total amount of the fibrin sheet.

[0061] As the fibrin sheet to which the present invention relates, in addition to the above-mentioned fibrin gel, the above-mentioned cells and the above-mentioned medicament, other components may be further contained. As such other components, components derived from the solvent of the following fibrinogen solution and thrombin solution may be cited, specifically components derived from solvents such as physiological saline for injection, buffer (phosphate buffer such as PBS, citric acid buffer, etc.), cell culture medium (DMEM, etc.); the added components of the following fibrinogen solution and thrombin solution may be specifically cosolvents such as surfactants, serum albumin (human serum albumin, etc.), sugar, sugar alcohol, amino acid (arginine, isoleucine, glutamic acid, etc.) or its salt, sodium citrate, sodium chloride, etc. In addition, in the case where the above-mentioned fibrin sheet is the above-mentioned cell sheet or the above-mentioned cell / medicament sheet, as the above-mentioned other components, proteins and / or glycoproteins (laminin (for example, laminin-221) etc.) and cell growth factors constituting the extracellular matrix may also be cited. As the above-mentioned other components, it may be a single one among them, or it may be a combination of more than two. The composition and content of these other components can be appropriately adjusted according to the types of cells, drugs and other components contained in the fibrin sheet, the purpose of use of the fibrin sheet, and the like.

[0062] The fibrin sheet according to the present invention is not particularly limited, but preferably has a concentration of 100 to 300 μL / 1 cm 2 The thickness of the fibrin sheet is preferably about 1 to 3 mm, and more preferably 1 to 3 mm. However, the fibrin sheet of the present invention can be formed into a three-dimensional biological material of a desired thickness by laminating the fibrin sheet. In addition, in the present invention, the area of ​​the fibrin sheet is not particularly limited and can be appropriately adjusted according to the purpose of use.

[0063] (Process 1)

[0064] In the method for producing a fibrin sheet of the present invention, first, a fibrinogen solution containing at least one selected from cells and drugs and fibrinogen is dropped onto the surface of a base material formed of gelatin hydrogel (step 1).

[0065] The substrate of the present invention is formed of gelatin hydrogel. In the present invention, the so-called "gelatin hydrogel" is a gel containing at least gelatin and water, and crosslinks are formed between the gelatin molecules.

[0066] The "gelatin" involved in the present invention is not particularly limited as long as it has cross-linking properties. It can be natural gelatin produced from the skin, bones, ligaments, tendons, etc. of animals such as cattle, pigs, whales, and fish, or a polypeptide or protein-like substance (recombinant gelatin) having an amino acid sequence similar to gelatin produced by genetic recombination technology. In addition, the above-mentioned natural gelatin can be type A gelatin (isoelectric point: 8 to 9) derived from so-called acid-cured tissue, or type B gelatin (isoelectric point: 4.8 to 5.0) derived from so-called lime-cured tissue. As such gelatin, commercially available products can be used appropriately.

[0067] In the above-mentioned gelatin hydrogel, crosslinking between the above-mentioned gelatin molecules can also be carried out by a chemical method using a crosslinking agent or the like, or a physical method using ultraviolet rays or the like. However, the gelatin hydrogel involved in the present invention is preferably a substance obtained by forming crosslinks between the above-mentioned gelatin molecules by a method (heat treatment method) of heating a gelatin aqueous solution containing gelatin and water and then cooling it, from the viewpoint of remelting properties by heating and the viewpoint of uniformity of the substrate surface.

[0068] As the above-mentioned gelatin aqueous solution, for example, a solution obtained by adding gelatin to an aqueous solvent can be mentioned. As the above-mentioned aqueous solvent, a solvent containing at least water can be used, and for example, distilled water for injection, physiological saline for injection, buffer (phosphate buffer such as PBS, citric acid buffer, etc.), cell culture medium (DMEM, etc.) can be mentioned. It can be a single one of them or a combination of two or more. Among them, when the fibrin sheet involved in the present invention is the above-mentioned cell sheet or the above-mentioned cell / drug sheet, as the above-mentioned aqueous solvent, it is preferred that the cell culture medium contains a cell culture medium suitable for the contained cells, and it is more preferred that the above-mentioned substrate is a substrate containing at least gelatin and the above-mentioned cell culture medium, that is, a substrate for cell culture.

[0069] The concentration of gelatin in the aqueous gelatin solution is preferably 1 to 12% by mass, more preferably 2 to 10% by mass, and even more preferably 3 to 8% by mass.

[0070] As conditions for preparing the gelatin hydrogel by the heat treatment method, for example, it is preferred that the gelatin aqueous solution is heated at 30 to 40° C., preferably 35 to 40° C., for 5 to 40 minutes, preferably 10 to 30 minutes, and then cooled at 0 to 20° C., preferably 4 to 10° C., for 5 to 120 minutes, preferably 10 to 60 minutes. Examples of the heating method include methods using a water bath or an incubator, and examples of the cooling method include methods of leaving the solution at room temperature (about 25° C.) or in a cold place.

[0071] The gelatin hydrogel can be obtained on a device such as a culture dish, a multi-well plate, a flask, or a microcarrier by placing the heated gelatin aqueous solution in the device and then cooling it. As the substrate of the present invention, it is preferred to directly use the gelatin hydrogel on such a device from the viewpoint of ease of handling, but the gelatin hydrogel can be peeled off from the device and used, or can be appropriately cut into a desired size and used.

[0072] The fibrinogen solution according to the present invention contains at least one selected from cells and drugs and fibrinogen. The cells, drugs, and fibrinogen are as described above including preferred embodiments thereof.

[0073] The contents of the cells and the drug in the fibrinogen solution are preferably appropriately adjusted so that the contents of the cells and the drug in the obtained fibrin sheet are within the above-mentioned preferred content ranges.

[0074] The content of fibrinogen in the fibrinogen solution is preferably 0.4 to 2% by mass, more preferably 0.4 to 1% by mass, in terms of protein amount. If the content of fibrinogen is less than the lower limit, formation of a fibrin gel tends to be difficult, while if the content exceeds the upper limit, the fibrin concentration of the fibrin gel tends to be high, making it difficult for cells to survive when contained therein.

[0075] As the solvent of the fibrinogen solution, a solvent commonly used as a solvent for dissolving fibrinogen can be used, for example, distilled water for injection, physiological saline for injection, buffer solution of pH 5 to 8 (phosphate buffer solution such as PBS, citric acid buffer solution, etc.), cell culture medium (DMEM, etc.) and other aqueous solvents can be mentioned, and they can be used alone or in combination of two or more. Among them, when the fibrin sheet is the cell sheet or the cell / drug sheet, as the solvent, it is preferred to contain a cell culture medium suitable for the cells contained therein.

[0076] The fibrinogen solution may further contain, in addition to the cells, the drug, and the fibrinogen, additives such as surfactants and other solubilizing agents, serum albumin (human serum albumin, etc.), sugars, sugar alcohols, amino acids (arginine, isoleucine, glutamic acid, etc.) or salts thereof, sodium citrate, sodium chloride, proteins and / or glycoproteins (laminin, etc.) constituting the extracellular matrix, cell growth factors, and the like, within the range not impairing the effects of the present invention.

[0077] There are no particular limitations on the method of dripping the fibrinogen solution onto the surface of the substrate, and examples thereof include dripping with a pipette and dripping with a syringe. The amount of dripping at this time is preferably 60 to 180 μL, more preferably 80 to 160 μL, and even more preferably 100 to 140 μL from the viewpoint of uniformity of the resulting fibrin sheet.

[0078] (Process 2)

[0079] In the method for producing a fibrin sheet of the present invention, after step 1, thrombin is added to the fibrinogen solution on the surface of the substrate (step 2). The thrombin is as described above including preferred embodiments thereof.

[0080] The amount of thrombin added to the fibrinogen solution is preferably 0.75 to 375 units (U) relative to 100 mg of fibrinogen (converted by protein amount). If the amount of thrombin added is less than the lower limit, the formation of a fibrin gel tends to be difficult. On the other hand, if the upper limit is exceeded, the fibrin concentration of the fibrin gel tends to be high, making it difficult for cells to survive when contained. In addition, in the present invention, the quantitative method of thrombin can be based on the "Toronbin quantitative method (thrombin quantitative method)" of the Japanese Pharmacopoeia.

[0081] In the present invention, as thrombin, it can be added as a thrombin solution containing thrombin. As the solvent of the above-mentioned thrombin solution, a commonly used solvent can be used, for example, distilled water for injection, physiological saline for injection, pH 5 to 8 buffer (phosphate buffer such as PBS, citric acid buffer, etc.), cell culture medium (DMEM, etc.) and other aqueous solvents can be mentioned, which can be a single one of them, or a combination of two or more. Among them, when the above-mentioned fibrin sheet is the above-mentioned cell sheet or the above-mentioned cell / drug sheet, as the above-mentioned solvent, it is preferred to contain a cell culture medium suitable for the contained cells.

[0082] In addition, the above-mentioned thrombin solution may further contain, in addition to thrombin, additives such as cosolvents such as surfactants, serum albumin (human serum albumin, etc.), sugars, sugar alcohols, amino acids (arginine, isoleucine, glutamic acid, etc.) or their salts, sodium citrate, sodium chloride, proteins and / or glycoproteins (laminin, etc.) constituting the extracellular matrix, cell growth factors, and the like, within the range not impairing the effects of the present invention.

[0083] There are no particular restrictions on the method of adding thrombin to the fibrinogen solution, and examples thereof include a method of adding the thrombin solution to the fibrinogen solution (preferably a drop of the fibrinogen solution) by a pipette, a method of attaching the thrombin solution to the lower surface of the support membrane and then placing it on the upper surface of the fibrinogen solution, and a method combining these. The amount of the thrombin solution added at this time is preferably 1 to 25 μL, more preferably 2 to 20 μL, and even more preferably 2 to 15 μL from the viewpoint of uniformity of the resulting fibrin sheet.

[0084] In step 2, the fibrinogen solution and the thrombin may be stirred by flushing or suction, but the fibrinogen solution to which the thrombin is added (hereinafter referred to as "fibrin precursor solution" depending on the situation) is preferably formed into drops directly on the substrate. In the present invention, the "drop" does not cover the entire surface of the substrate, and the volume (μL) of the drop is proportional to the contact area (mm2) of the substrate. 2 ) is preferably 0.5 μL / mm 2 More preferably, 1 μL / mm 2 above.

[0085] (Process 3)

[0086] In the method for manufacturing a fibrin sheet of the present invention, the support membrane is placed in contact with the upper surface of the fibrinogen solution to which the thrombin is added (step 3). In step 3, the support membrane is placed on the upper surface of the fibrin precursor solution (preferably the drop of the fibrin precursor solution) in a contacting manner, so that the fibrin precursor solution can be evenly spread by the dead weight of the support membrane and the surface tension between the drop of the fibrin precursor solution and the support membrane, and the obtained fibrin sheet can be made to fit closely with the support membrane. In the case where step 3 is performed after step 2, it is preferred that the formation of the fibrin sheet of the following step 4 is performed simultaneously after step 2, so in the step 3, it is preferred that the support membrane is placed on the upper surface of the fibrin precursor solution immediately after the addition of thrombin to the fibrinogen solution, preferably within 5 minutes, and more preferably within 2 minutes. In addition, step 2 (addition of thrombin to the fibrinogen solution) and step 3 may be performed simultaneously, for example, by allowing the thrombin solution to adhere to the lower surface of the support membrane (preferably after the thrombin solution is dripped and spread out) and then placing it on the upper surface of the fibrinogen solution (preferably the drops of the fibrin solution), etc., thereby allowing step 2 and step 3 to be performed simultaneously.

[0087] In the present invention, as a "support film", as long as it is a film that can support the obtained fibrin sheet and maintain its shape, there is no particular limitation, preferably a film that is easy to peel off from the fibrin sheet when the fibrin sheet is used, and in addition, the surface in contact with the above-mentioned fibrin precursor liquid is preferably a uniform surface with few concave-convex surfaces. As such a support film, for example, polypropylene sheets, polyethylene, paper, metals such as titanium and aluminum, glass, and a combination of two or more thereof can be cited. Among them, as the above-mentioned support film, from the viewpoint of surface uniformity, ease of operation, and ease of peeling off from the fibrin sheet, a polypropylene sheet is preferably used.

[0088] In addition, the weight per unit area of ​​the support film is preferably 0.01 to 0.2 g / cm from the viewpoint of obtaining a fibrin sheet of suitable thickness by its own weight. 2 , more preferably 0.01 to 0.1 g / cm 2 , more preferably 0.01 to 0.05 g / cm 2 .

[0089] The area of ​​the support membrane is preferably 50 to 200 mm2 per 100 μL of the fibrin precursor solution. 2 , more preferably 50 to 150 mm 2 , more preferably 75 to 100 mm 2 . The shape of the support membrane is not particularly limited, and any shape can be selected, such as a polygon such as a circle, an ellipse, a square, a rectangle, a shape with a hole, a shape in which an incision is introduced in a bent manner on the surface opposite to the surface in contact with the fibrin sheet, etc. By using a support membrane having a shape in which an incision is introduced on the surface opposite to the surface in contact with the fibrin sheet, the fibrin sheet can be folded, for example, a fibrin sheet of a larger area can be transplanted with a small incision. Furthermore, the thickness of the support membrane is not particularly limited, but from the viewpoint of ease of operation, it is preferably 0.05 to 0.4 μm.

[0090] (Process 4)

[0091] In the method for producing a fibrin sheet of the present invention, a fibrin sheet containing at least one of the cells and the drug is formed in a fibrin gel by the reaction of fibrinogen and thrombin between the substrate and the support membrane (step 4). The fibrin sheet, the cells, the drug, the fibrin gel, and other components as required, including the preferred embodiments thereof, are as described above. In the present invention, the formation of the fibrin sheet is started by step 2, so a part of step 4 can be performed simultaneously with step 2 and / or step 3.

[0092] In step 4, the reaction conditions of fibrinogen and thrombin are, for example, preferably standing at 4 to 25° C., preferably 4 to 20° C., for 5 to 20 minutes, preferably 5 to 15 minutes. By reacting fibrinogen and thrombin to form a fibrin gel, the fibrin sheet can be obtained between the substrate and the support membrane through step 4.

[0093] (Process 5)

[0094] In the method for producing a fibrin sheet of the present invention, after step 4, the base material is melted at a temperature not lower than the melting temperature of the gelatin hydrogel, and the fibrin sheet supported by the support membrane is separated from the base material (step 5).

[0095] In step 5, the temperature for melting the substrate may be any temperature above the melting temperature of the gelatin hydrogel, that is, above the melting temperature of the gelatin hydrogel after solidification. Specifically, the temperature for melting the substrate is preferably 30 to 40° C., and more preferably 35 to 40° C., from the viewpoint of inhibiting cell death and inactivation of the drug and facilitating separation of the fibrin sheet from the substrate. The time for melting the substrate at the temperature is not particularly limited, but is preferably 10 to 60 minutes, and more preferably 10 to 30 minutes, for example.

[0096] In step 5, there is no particular limitation on the method for melting the substrate, and examples thereof include a method of leaving the substrate, the fibrin sheet, and the support membrane after step 4 to stand under the above conditions on a water bath or in an incubator. By such step 5, the gelatin hydrogel constituting the substrate is melted, so that the adhesion between the fibrin sheet and the surface of the substrate is released, and by recovering the support membrane, the fibrin sheet laminated and supported on the support membrane can be recovered.

[0097] According to the present invention, even if the fibrin concentration is a low concentration at which cells can survive, a fibrin sheet can be easily manufactured, so when the fibrin sheet is the cell sheet or the cell / drug sheet, cells can be contained in a viable state in the fibrin sheet. In addition, cells can migrate in a fibrin sheet with a low fibrin concentration, so according to the present invention, a fibrin sheet in which cells are three-dimensionally dispersed or a fibrin sheet in which cells are aggregated on the surface of the sheet can be manufactured.

[0098] The fibrin sheet obtained by the present invention can be used directly as a cell sheet and / or a drug sheet, and can be used for the treatment of diseases using cell transplantation (cell supplementation therapy), the repair / reinforcement of the incision and / or the tissue defect after the lesion is removed during surgery. In addition, the fibrin sheet obtained by the present invention can also be laminated to form a three-dimensional biological material, and can also be used for transplantation, drug development research, etc.

[0099] As an example of a treatment method using the fibrin sheet obtained by the present invention, a treatment method for heart disease using cell transplantation using the cell sheet obtained by the production method of the present invention is described below. In addition, as a treatment method using the fibrin sheet obtained by the present invention, for example, from the viewpoint of replenishing and strengthening cells of defective tissues / organs with reduced functions, hepatic function reduction such as cirrhosis and viral hepatitis, gastrointestinal ulcers, gastrointestinal perforations, epithelial ulcers, epithelial defects, corneal damage, and hemostasis of bleeding sites accompanied by blood vessel / organ damage can also be treated.

[0100] Examples of the "heart disease" that is the subject of the above-mentioned treatment method include diseases selected from the group consisting of heart failure, ischemic heart disease, myocardial infarction, cardiomyopathy, myocarditis, hypertrophic cardiomyopathy, dilated hypertrophic cardiomyopathy, and dilated cardiomyopathy.

[0101] The above-mentioned treatment method for heart disease can be applied to humans and non-human objects. As long as the organism that becomes the object of application has a heart that is the target of treatment, there is no particular limitation, and examples thereof include humans, mammals other than humans, birds, reptiles, amphibians, and fish. Mammals other than humans include, in addition to primates such as chimpanzees and monkeys, livestock and pets such as cattle, pigs, horses, chickens, cats, and dogs, but are not limited thereto. As cells contained in the above-mentioned cell sheet, it is sufficient to use cells of a source suitable for the organism that becomes the object of these treatments, but from the viewpoint of suppressing rejection reactions, cells of the same species, particularly preferably of autologous origin, are preferred.

[0102] In the above-mentioned treatment method for heart disease, it is preferred to coat the heart surface (preferably the lesion (e.g., myocardial infarction lesion)) of a subject suffering from heart disease with the above-mentioned cell sheet. In the transplantation of the above-mentioned cell sheet to the heart surface, since the cell sheet is a fibrin sheet, it can be easily fixed by sticking the cell sheet to the heart surface.

[0103] The above-mentioned treatment methods for heart disease can be used in combination with other treatments as appropriate. Such other treatments include, for example, coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, and left ventriculoplasty in chronic myocardial infarction, and coronary artery bypass surgery, percutaneous transluminal coronary angioplasty in acute myocardial infarction. In addition, it can also be used in combination with valve replacement surgery and pediatric heart surgery.

[0104] Example

[0105] Examples of the present invention are described below, but the present invention is not limited to these examples.

[0106] (Example 1)

[0107] <Materials>

[0108] iPS-CMs: cardiomyocytes derived from human iPS cells

[0109] DMEM: DMEM high glucose (nacalai tesque, Code 08458-16),

[0110] PBS: D-PBS(-)(nacalai tesque, Code 14249-24),

[0111] Gelatin: Gelatin from pig skin (Sigma, G1890-100G),

[0112] Fibrinogen: Beriplast P Combi-set solution A (CSL Behring, 87799),

[0113] Thrombin: Beriplast P Combi-set solution B (CSL Behring, 87799),

[0114] Polypropylene sheet (PP sheet): area: 10 mm×10 mm, thickness: 0.3 μm.

[0115] <Manufacturing of fibrin sheets>

[0116] First, 1.6 g of gelatin was added to 40 mL of DMEM and dissolved in a 37°C water bath for 10 to 20 minutes to prepare a 4 w / v% (g / mL%, the same below) gelatin solution. Next, 3 mL of the above gelatin solution was added to each well of a 6-well plate and cooled at 4°C for 20 minutes to form a gelatin hydrogel, thereby preparing a substrate formed of a gelatin hydrogel. In addition, foreign matter was removed using a 70 μm filter, and 100 μL (5×10 6cells), 10 μL of fibrinogen prepared by diluting Beriplast P solution A 2-fold with DMEM and 120 μL of fibrinogen solution prepared by diluting Beriplast P solution A 10 μL with PBS 10 μL were mixed and immediately and rapidly added dropwise to the surface of the substrate (about 4°C) (Step 1). Next, 2 μL of thrombin solution prepared by diluting Beriplast P solution B (0.03 U / μL) 10-fold with DMEM was added to the fibrinogen solution on the surface of the substrate (Step 2), and a polypropylene sheet (support membrane) was rapidly placed in contact with the upper surface of the fibrinogen solution to which the thrombin solution was added (Step 3). After being allowed to stand at 4°C for 10 minutes and confirming that the fibrinogen solution hardened and formed a fibrin gel (fibrin sheet) (Step 4), the substrate formed by the gelatin hydrogel was melted in a 37°C incubator for 20 minutes (Step 5), and the fibrin gel (containing 5×10 cells in the fibrin gel) was recovered together with the polypropylene sheet. 6 The area of ​​the obtained fibrin sheet was 1 cm 2 The morphology of the substrate, fibrin sheet, and support membrane in step 4 is shown in Figure 1 The morphology of the melted substrate, fibrin sheet, and support membrane in step 5 is shown in FIG. Figure 2 Furthermore, the morphology of the fibrin sheet obtained in step 6 is shown in Figure 3 In. Figure 3 As shown, the obtained fibrin sheet was a uniform sheet without irregularities. In addition, in the obtained fibrin sheet, cells were gathered in the surface layer to form a tissue with a thickness of 100 to 150 μm.

[0117] Furthermore, by increasing the amount of the fibrinogen solution and the thrombin solution and increasing the area of ​​the polypropylene sheet, it was confirmed that a fibrin sheet having a large area could be obtained in the same uniform manner. The morphology of the fibrin sheet obtained by increasing the area is shown in FIG. Figure 4 middle.

[0118] <Evaluation of fibrin sheets>

[0119] Two weeks after myocardial infarction in nude rat myocardial infarction models, the fibrin sheet was attached to the surface of the para-infarct site of the myocardium and transplanted. After transplantation, cardiac function (contractile energy, end-systolic diameter, end-diastolic diameter) was evaluated by echocardiography every week until the fourth week. In addition, the expression level of VEGF (cytokine) gene in the para-infarct site at the fourth week after transplantation was measured by qPCR.

[0120] exist Figure 5, the results of evaluating cardiac function in a nude rat myocardial infarction model transplanted with the fibrin sheet (transplantation group n: 8) and a nude rat myocardial infarction model without the fibrin sheet (control n: 5) are shown. Figure 5 The vertical axis (EF (%)) is the left ventricular ejection fraction. Figure 5 As shown, in rats transplanted with the fibrin sheet (transplantation group), significant improvement in cardiac function was observed 4 weeks after the transplantation.

[0121] In addition, Figure 6 Graphs in the figure show the results of measuring the expression level of VEGF gene in nude rat myocardial infarction models transplanted with the fibrin sheet (transplantation group n: 8) and nude rat myocardial infarction models without the fibrin sheet (control n: 5). Figure 6 The vertical axis shows the expression level of VEGF gene relative to the control group. Figure 6 As shown, in rats transplanted with the fibrin sheet (transplantation group), the expression of VEGF gene, a cytokine associated with angiogenesis, was confirmed to be enhanced in the para-infarcted area. In addition, in the transplantation group, it was confirmed that the size of the myocardium in the para-infarcted area was significantly reduced, myocardial hypertrophy was suppressed, and further, angiogenesis was confirmed to be improved.

[0122] Industrial Availability

[0123] As described above, according to the present invention, it is possible to provide a method for producing a fibrin sheet, which can easily produce a fibrin sheet containing at least one selected from cells and drugs in a fibrin gel uniformly and in an arbitrary shape while suppressing damage to cells and drugs even when the fibrin concentration is a low concentration at which cells can survive.

Claims

1. A method for producing a fibrin sheet, comprising the steps of: Step 1, dropping a fibrinogen solution onto the surface of a substrate formed of a gelatin hydrogel, wherein the fibrinogen solution contains fibrinogen and at least one selected from cells and drugs; Step 2, adding thrombin to the fibrinogen solution on the surface of the substrate; Step 3, placing the support membrane in contact with the upper surface of the fibrinogen solution to which the thrombin is added; Step 4, forming a fibrin sheet containing at least one selected from the group consisting of cells and drugs in a fibrin gel by reacting fibrinogen with thrombin between the substrate and the support membrane; and Step 5, melting the substrate at a temperature not lower than the melting temperature of the gelatin hydrogel and not higher than 40° C., and separating the fibrin sheet supported by the support membrane from the substrate, In step 1, the content of fibrinogen in the fibrinogen solution is 0.4 to 2% by mass in terms of protein. In step 2, the amount of thrombin added is 0.75 to 375 U per 100 mg of fibrinogen converted to protein amount. In step 3, the support membrane is a membrane capable of supporting the obtained fibrin sheet and maintaining its shape. 2 . The method for producing a fibrin sheet according to claim 1 , wherein the fibrin sheet is a cell sheet containing at least cells in the fibrin gel, and the substrate is a substrate for cell culture.

3. The method for producing a fibrin sheet according to claim 1 or 2, further comprising, before step 1: A step of heating a gelatin aqueous solution containing gelatin and water and then cooling it to obtain the gelatin hydrogel. The method for producing a fibrin sheet according to claim 1 or 2, wherein the support membrane is a polypropylene sheet. 5 . The method for producing a fibrin sheet according to claim 1 , wherein in the step 5, the base material is melted at 30 to 40° C.

Citation Information

Patent Citations

  • Anodes for electrochemical purposes

    EP0002017A1

  • Cell sheet engineering and preparation method thereof

    CN101629162A

  • Compositions and methods using stem cells in cutaneous wound healing

    CN102046188A

  • Cytokine-producing cell sheet and method for using same

    CN103476439A

  • Stem cell exosome patch and preparation method and application thereof

    CN104894062A